

Anti-P-TYR [PY793]

| Catalog No. | Description | |
|---|--|--|
| AM938-5ME 6 ml of Ready-to-Use Antibody for use we BioGenex Super Sensitive TM Detection Systems OR equivalent detection systems | | |
| AM938-10ME 10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGen Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems | | |
| MU938-UCE | 1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system | |
| MU938-5UCE | 0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system | |
| AX938-YCDE Ready-to-Use Antibody in Barcode vial for use on the Xmatrx® Elite/U Staining System, 160 tests | | |
| AX938-50DE | Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite/Ultra Staining System, 50 tests | |

| Clone | Species | Ig Class |
|-------|---------|----------|
| PY793 | Mouse | IgG2b |

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of P-TYR in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Protein phosphorylation is a fundamental event in the regulation of a large number of intracellular processes. Phosphorylation of specific tyrosine residues is the result of activation or stimulation of their respective protein tyrosine kinases. Tyrosinephosphorylated proteins are involved in signal transduction and in the regulation of cell proliferation. Antibody to phosphotyrosine provides an excellent tool for the detection, characterization, and purification of phosphotyrosine containing proteins. This MAb shows no cross-reaction with other phosphoamino acids and is superb for multiple applications including staining of formalin/paraffin tissue.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody P-TYR is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

| Parameter | BioGenex Recommendations | |
|--|---|--|
| Control Tissue | Prostate and stomach cancer tissue as available with Biogenex FB-938ME* & FG-938ME* | |
| Recommended Dilution for Concentrated Antibody | 1:100 in HK156 | |
| Recommended Pretreatment (Manual/i6000)** | EZ-AR1 (HK521-XAK)/EZ- AR1 Elegance (HK546-XAK) | |
| Recommended Pretreatment (Xmatrx) | EZ-AR1 Elegance (HX031- YCD) | |
| Antibody Incubation (Manual/i6000) | 30 Min at RT | |
| Antibody Incubation (Xmatrx) | 30 Min at RT | |
| Detection System for Manual, Xmatrx & i6000 systems*** | Use BioGenex Two-Step OR One-Step Super Sensitive [™] Polymer-HRP IHC Detection System/DAB; see p. 2 for more information | |

*FB: positive control barrier slides, FG: positive control nonbarrier slides. Xmatrx requires barrier slides.

Pretreatment times will vary based on individual microwave power. *For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

| Category | Antibodies | Revision No. | В |
|--------------|-------------|--------------|-------------|
| Document No. | 932-938M-EN | Release Date | 11-Jun-2021 |



| ((| Emergo Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlands |
|--------|--|
| EC REF | |

| Detection | Two-Step | One-Step | Link and |
|---|--|---------------------------|---------------------------|
| System | HRP Kit | HRP Kit | Label Kit |
| Manual | QD440-XAKE (1000 Test) QD430-XAKE (1000 Test) | QD630-XAKE (1000 Test) | QP300-XAKE (1000 Test) |
| Manual | QD420-YIKE (500 Test) QD400-60KE (60 Test) | QD620-XAKE (500 Test) | QP900-9LE (500 Test) |
| Xmatrx - | QD550-YCDE | QD610-YADE | N/A |
| Automation | (200 Test) | (200 Test) | |
| i6000 - | QD410-YAXE | QD610-YAXE | N/A |
| Automation | (200 Test) | (200 Test) | |
| For more information, visit <u>www.biogenex.com</u> . | | | |

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains cell membrane in positive cells in formalinfixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- 1. Hunter, T., et al. Protein-tyrosine kinases. Annu. Rev. Biochem. 1985; 54: 897-930.
- Arad-Dann H1, Beller U, Haimovitch R, Gavrieli Y, Ben-Sasson SA. Immunohistochemistry of phosphotyrosine residues: Identification of distinct intracellular patterns in epithelial and steroidogenic tissues. J Histochem Cytochem. 1993 Apr;41(4):513-9.
- Justin M. Drake, Nicholas A. Graham, et al. Oncogenespecific activation of tyrosine kinase networks during prostate cancer progression. PNAS, 2012 January. 109 (5): 1643-1648

| 2°C 8°C | Temperature Limitation | IVD | In Vitro Diagnostic Medical Device |
|----------------|---|-----|---|
| \boxtimes | Use By Date | LOT | Batch Code |
| NON STERILE | Non-Sterile | []i | Consult Instructions for Use |
| EC REP | Representative in the European Community | • | Manufacturer |

© 2020, BioGenex Laboratories. All rights reserved.

| Category | Antibodies | Revision No. | В |
|--------------|-------------|--------------|-------------|
| Document No. | 932-938M-EN | Release Date | 11-Jun-2021 |